KOPRAN LTD.

Kopran Ltd has announced its 67th Annual General Meeting (AGM) scheduled for August 18, 2026, to be held via Video Conferencing. The company has also enclosed the Annual Report for the financial year 2025-26, in compliance with SEBI regulations. The report details the company's corporate overview, financial highlights, business operations, and financial statements. Kopran emphasizes its strategy of innovation, integration, and diversification in the pharmaceutical sector, highlighting its capabilities in APIs and Formulations. The report is being sent electronically to shareholders and is available on the company's website.

Kopran Ltd has announced that its Board of Directors will convene on August 7, 2026, to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The meeting is scheduled to be held at the company's registered office. Following the declaration of these financial results, the trading window for dealing in the company's securities, which was closed from July 1, 2026, will be reopened 48 hours after the announcement.

Kopran Ltd has announced Tuesday, August 11, 2026, as the record date for the payment of dividend, subject to declaration by the company's members at the Annual General Meeting (AGM) scheduled for Tuesday, August 18, 2026. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The dividend payment is contingent on the approval at the AGM, and applicable tax will be deducted at source.

Kopran Ltd has announced the appointment of Mr. Vijay L Thange as its new Chief Technical Officer (CTO), effective June 26, 2026. Mr. Thange brings over 36 years of extensive experience in the pharmaceutical sector, having previously held senior positions at companies like CIPLA, RPG Life sciences, and most recently as Vice President – Plant Operation at USV Limited. His qualifications include BSc, LLB, PGD(Operation), and MBA with a specialization in Operations Management. This appointment is in compliance with SEBI Listing Regulations.

Kopran Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 01, 2026, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the first quarter ended June 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code for fair disclosure of unpublished price-sensitive information. The specific date for the board meeting to approve these results will be communicated later. This measure is standard practice to prevent insider trading during the sensitive period leading up to financial result announcements.

Kopran Ltd has announced its standalone and consolidated audited financial results for the fourth quarter and year ended March 31, 2026. The Board of Directors approved the results on May 19, 2026. The board has recommended a dividend of ₹3.00 per equity share (30%) for the financial year ended March 31, 2026, subject to shareholder approval. Additionally, Mrs. Namrata Somani has been appointed as an Additional Director (Non-Executive, Promoter Group).

Kopran Ltd announced the appointment of Mr. Chandresh Gandhi as an Additional Director (Non-Executive, Independent Category) of its subsidiary, Kopran Research Laboratories Limited (KRLL), for a five-year term starting May 18, 2026. KRLL will also issue rights shares at a premium of ₹90 each, utilizing the raised funds (₹18.75 Cr) for working capital.

Kopran Ltd. will hold a shareholders meeting on June 3, 2026, as directed by the National Company Law Tribunal (NCLT), Mumbai Bench. The meeting addresses the scheme of amalgamation between Kopran Laboratories Limited and Kopran Limited. The scheme's implementation will result in a decrease in public shareholding from 55.57% to 44.67% and an increase in promoter shareholding from 44.43% to 55.33%. Shareholders are advised to review all scheme-related documents before voting. Remote e-voting will be available from May 27 to June 2, 2026.

Kopran Ltd has scheduled a Board of Directors meeting on May 19, 2026, to consider and approve the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026. The board will also consider and recommend a dividend, if any. The trading window, which was closed from April 1, 2026, will re-open 48 hours after the declaration of the financial results.

Kopran Ltd has announced that it will convene meetings of its equity shareholders, secured creditors, and unsecured creditors on Wednesday, June 03, 2026. These meetings are being held pursuant to an NCLT order dated April 09, 2026. The primary agenda is to consider and approve the Scheme of Amalgamation (Merger by Absorption) of Kopran Laboratories Limited (Transferor Company) with Kopran Limited (Transferee Company). Separate meetings will also be held for the equity shareholders, secured, and unsecured creditors of Kopran Laboratories Limited on the same day. All meetings will be conducted through Video Conferencing/Other Audio-Visual Means (VC/OAVM). Notices for these meetings are being dispatched electronically and physically.